HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

XanGo Brochures Draw FDA Warning Letter For Unsubstantiated Claims

This article was originally published in The Tan Sheet

Executive Summary

An FDA Warning Letter citing unapproved new drug claims for XanGo Mangosteen juice that XanGo said were made by a third party underscores the agency's position on the responsibility supplement manufacturers assume for unsubstantiated label statements

You may also be interested in...



FDA on labeling

Under the Food, Drug & Cosmetic Act "'labeling' is not limited to labels on the immediate containers for your products," FDA reminds Osceola, Wisc.-based supplement marketer NeuroScience. Claims in brochures on weight control, attention deficit hyperactivity disorder and depression position the firm's products as unapproved new drugs, FDA says in an Oct. 11 letter. Claims cited by the agency include, "neurotransmitter imbalances can trigger ADHD" and "if an imbalance is detected, the technical staff at NeuroScience works with your healthcare provider to develop a Targeted Amino Acid Therapy protocol to address the imbalance." FDA sent a letter to Xango Sept. 20 regarding claims made in third-party brochures for XanGo mangosteen juice (1"The Tan Sheet" Oct. 9, 2006, p. 12)...

FDA, CRN Say Proper Supplement Labeling Can Enhance Consumer Trust

The current implementation of health claims and labeling information for foods and supplements is not adequately informing consumers on how to make healthy dietary choices, according to CFSAN's Barbara Schneeman, PhD

Hemp Supplement Sales Continue In US Without FDA Acknowledgement As Lawful Products

Decision, explained by Principal Deputy Commissioner Woodcock, turns page on FDA’s 2019 announcement, after hemp was de-scheduled in 2018 farm bill, it would consider rulemaking for lawful use of hemp in supplements.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS125990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel